What happened with AZN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
AstraZeneca makes medicines for patients with cancer and other diseases. Cancer treatments are its largest business, including Tagrisso and Imfinzi. It also has substantial businesses in cardiovascular, kidney and metabolic diseases, respiratory and immune conditions, and rare diseases; Farxiga/Forxiga is its biggest-selling individual medicine.
Most revenue comes from medicine sales. Wholesalers buy a significant share of its products for onward distribution to healthcare providers and pharmacies. Two wholesalers account for a substantial share of sales, making them important customers. Rebates and negotiated discounts reduce what AstraZeneca ultimately earns, while governments and healthcare payers influence prices and patient access.
The business depends on developing medicines that demonstrate safety and effectiveness, securing regulatory approval and successfully bringing them to market. Regulators can require further testing or restrict approved uses. Patent protection helps sustain sales, but patents can be challenged, and generic competition can reduce revenue when protection expires or is lost.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Roche is missing from this list, but its Tecentriq competes with Imfinzi and makes it a company to watch for AstraZeneca’s oncology growth.
Merck shares AstraZeneca’s profits from Lynparza sales, but its Keytruda competes with Imfinzi in cancer immunotherapy. Merck’s Lynparza profit-share revenue grew 11% in 2025, offering a direct read on the shared medicine’s commercial performance.
Novartis competes with AstraZeneca for prescription-medicine sales in oncology and cardiovascular disease, and directly challenges its marketing of treatments for paroxysmal nocturnal haemoglobinuria. Watch the October 2025 lawsuit alleging misleading marketing statements; those allegations are not established findings.
GSK competes with AstraZeneca to sell asthma and COPD medicines to respiratory specialists and cancer treatments to oncologists. Its asthma and COPD medicine business is the clearest area to watch alongside AstraZeneca’s respiratory sales.
Bristol Myers Squibb’s Opdivo competes with AstraZeneca’s Imfinzi for cancer-immunotherapy use. Its lung-cancer trial results and adoption of Opdivo are the news to watch for the competitive position of Imfinzi.
Eli Lilly competes with AstraZeneca through its Jardiance partnership in diabetes, heart failure and kidney disease, where Farxiga is a rival treatment. Lilly’s Jaypirca also competes with Calquence in blood-cancer treatment.
Sanofi sells and records revenue from Beyfortus, the antibody protecting infants from RSV, while AstraZeneca leads development and manufacturing, so both benefit from its uptake. Watch Sanofi’s Beyfortus sales rather than treating AstraZeneca’s product sales alone as the full picture; AstraZeneca also receives alliance revenue.
Amgen sells the shared severe-asthma medicine Tezspire in the US, while AstraZeneca markets it outside the US and receives alliance revenue. Amgen’s US Tezspire sales rose 52% to $1.478 billion in 2025, a concrete measure of uptake in the market where AstraZeneca reports no product sales.
BeOne Medicines competes with AstraZeneca through Brukinsa against Calquence and Tevimbra against Imfinzi. Brukinsa, its leading blood-cancer medicine, generated $3.9 billion in 2025 sales, making that product’s sales the clearest comparison for Calquence.
Johnson & Johnson competes with AstraZeneca through Imbruvica against Calquence, while its amivantamab-based lung-cancer treatments challenge Tagrisso.
Regeneron’s Dupixent, partnered with Sanofi, competes with AstraZeneca’s Fasenra and Tezspire for severe-asthma treatment and with its respiratory medicines in COPD.
AbbVie’s Imbruvica competes directly with AstraZeneca’s Calquence for patients with B-cell cancers. Watch developments in Imbruvica-based combination treatments for previously untreated chronic lymphocytic leukaemia, where the supplied filings also identify AstraZeneca’s treatment as a competitor.
Pfizer’s Ibrance and Talzenna compete in breast-cancer treatment markets also served by AstraZeneca’s Enhertu and Lynparza.
Novo Nordisk competes with AstraZeneca’s Farxiga for diabetes-treatment spending, and both companies have marketed competing GLP-1 injections. Novo Nordisk’s diabetes-medicine business is the relevant comparison, rather than its whole portfolio.
Gilead Sciences’ Trodelvy competes with AstraZeneca’s Enhertu and Datroway in overlapping breast-cancer treatment settings.
Ionis Pharmaceuticals, Inc. jointly sells Wainua with AstraZeneca in the US and receives payments tied to AstraZeneca’s sales outside the US, so their commercial interests move together. Ionis reports earned Wainua royalties as commercial revenue, giving investors a specific line to watch for the shared medicine’s sales progress.
Alnylam’s Amvuttra and Onpattro compete with AstraZeneca and Ionis’s Wainua for treatment of ATTR amyloidosis.
HUTCHMED and AstraZeneca both depend on the commercial success of savolitinib, which they market together as Orpathys. Watch Orpathys sales in China, where this internally developed HUTCHMED cancer medicine is commercially available.
Compugen Ltd depends on AstraZeneca’s progress with rilvegostomig for potential milestone payments and sales royalties, having licensed the antibody component that binds TIGIT. Watch rilvegostomig’s late-stage cancer trials: safety problems or lack of efficacy would matter to AstraZeneca’s drug prospects and Compugen’s future payments.
Merck & Co., Inc. earningsMRK
Merck’s report will show how Lynparza, which it shares commercially with AstraZeneca, is selling and contributing to their partnership.
Look for Merck’s Lynparza sales and profit-share contribution. Growth in both would show that the medicine is contributing more to AstraZeneca through their partnership; weakness would mean less support from that collaboration. Merck’s Keytruda competes with Imfinzi, but that is a separate business signal.
AstraZeneca PLC earningsThis company
AstraZeneca’s report will show how much medicine-sales growth reaches its revenue after US rebates and chargebacks.
Compare gross product sales with net product sales after rebates and chargebacks, alongside sales of major medicines. If net sales keep pace with gross sales, more of the invoiced value is reaching AstraZeneca. If the gap widens, rebates and chargebacks are absorbing more of the sales growth.
Amgen Inc earningsAMGN
Amgen’s report will show US demand for Tezspire, which Amgen sells in the US while AstraZeneca sells it elsewhere and receives alliance revenue.
Look at Amgen’s US Tezspire sales. Rising sales would show broader uptake of the shared medicine in a market where AstraZeneca records no product sales, strengthening the commercial basis for its alliance revenue. Falling sales would point to weaker demand momentum for Tezspire.
Ionis Pharmaceuticals, Inc. earningsIONS
Ionis’s report will show Wainua’s sales progress; AstraZeneca co-sells the medicine with Ionis in the US and pays Ionis based on sales outside the US.
Look for Ionis’s Wainua royalties and other commercial revenue, keeping US sales distinct from sales outside the US. Stronger revenue would point to better progress for the shared medicine, supporting AstraZeneca’s US sales while increasing payments tied to sales elsewhere; weaker revenue would signal a smaller sales contribution.
BeOne Medicines Ltd. earningsONC
BeOne Medicines’ report will show how Brukinsa is selling against AstraZeneca’s Calquence for blood-cancer patients and prescriptions.
Focus on BeOne Medicines’ Brukinsa sales. Continued growth would show the rival gaining more business in blood-cancer treatment and put greater competitive pressure on Calquence; slower or falling sales would suggest less pressure.
